Cladribine for multiple sclerosis: Review and current status

Expert Review of Neurotherapeutics

Volumn 5, Issue 6, 2005, Pages 721-727

  Sipe, Jack C ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

2 chloro 2 deoxyadenosine; Cladribine; Immunosuppressive therapy; Lymphotoxicity; Multiple sclerosis

Indexed keywords

CARBAMAZEPINE; CHEMOKINE; CHLORAMBUCIL; CLADRIBINE; COMPLEMENT; CORTICOSTEROID; CYTARABINE; FLUDARABINE; PHENYTOIN; PLACEBO; PURINE DERIVATIVE;

ANEMIA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CYTOPENIA; CYTOTOXICITY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GRANULOCYTOPENIA; HAIRY CELL LEUKEMIA; HEPATITIS B; HERPES ZOSTER; HUMAN; INFECTION COMPLICATION; INFECTION RISK; LEUKOPENIA; LYMPHATIC SYSTEM TUMOR; LYMPHOCYTOPENIA; MARKETING; MEGALOCYTOSIS; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; REVIEW; TABLET; THROMBOCYTOPENIA;

CLADRIBINE; DRUG INTERACTIONS; EXPERT TESTIMONY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; META-ANALYSIS; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 27944443692     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.5.6.721     Document Type: Review

References (54)

1. Carson DA, Wasson DB, Beutler E. Antileukemic and immunosuppressive activity of 2-chloro-2′-deoxyadenosine. Proc. Natl Acad. Sci. 81, 2232-2236 (1984).
2. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet 340, 952-956 (1992).
3. Beutler E, Carson DA. 2-Chlorodeoxyadenosine: hairy cell leukemia takes a surprising turn. Blood Cells 19, 559-568 (1993).
4. Beutler E. New chemotherapeutic agent: 2-chlorodeoxyadenosine. Semin. Hematol. 31, 40-45 (1994).
5. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J. Clin. Oncol. 13, 570-574 (1995).
6. Saven A, Piro LD, Lemon RH. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73, 2953-2963 (1994).
7. Piro LD, Carrera CJ, Beutler E, Carson DA. 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72, 1069-1073 (1988).
8. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N. Engl. J. Med. 322, 1117-1121 (1990).
9. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 11, 679-689 (1993).
10. Juliusson G, Heldal D, Hippe E. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. J. Clin. Oncol. 13, 989-995 (1995).
11. Liliemark J, Martinsson U, Cavallin-Stahl E. Cladribine for untreated or early low-grade non-Hodgkin's lymphoma. Leuk. Lymphoma 30, 573-581 (1998).
12. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2- chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80, 587-592 (1992).
13. Saven A, Piro LD. 2-chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders. Hematol. Cell Ther. 38(Suppl. 2), S93-S101 (1996).
14. Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J. Clin. Oncol. 14, 2139-2144 (1996).
15. Figueroa M, McMillan R. 2-chlorodeoxyadenosine in the treatment of chronic refractory immune thrombocytopenic purpura. Blood 81, 3484-3485 (1993).
16. Eibschutz B, Baird SM, Weisman MH. Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report. Arthritis Rheum. 38, 1604-1609 (1995).
17. Voulgarelis M, Petroutsos G, Moutsopoulos HM, Skopouli FN. 2-chloro-2′-deoxyadenosine in the treatment of Sjogren's syndrome-associated B cell lymphoproliferation. Arthritis Rheum. 46, 2248-2249 (2002).
18. Merkel PA, Letourneau EN, Polisson RP. Investigational agents for rheumatoid arthritis. Rheum. Dis. Clin. North Am. 21, 779-796 (1995).
19. Beutler E, Carson D, Sipe JC et al. 2-chlorodeoxyadenosine in nonmalignant disorders. In: Nucleoside Analogues in Cancer Therapy. Marcel Dekker, Inc., NY, USA, 359-382 (1997).
20. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2, 1067-1069 (1972).
21. Carson DA, Kaye J, Seegmiller JE. Lymphospecific toxicity in adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency: possible role of nucleoside kinase(s). Proc. Natl Acad. Sci. 74, 5677-5681 (1977).
22. Carson DA, Wasson DB, Kaye J. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. 77, 6865-6869 (1980).
23. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62, 737-743 (1983).
24. Liliemark J. The clinical pharmacokinetics of cladribine. Clin. Pharmacokinet. 32, 120-131 (1997).
25. Tortorella C, Rovaris M, Filippi M. Cladribine. Ortho Biotech Inc. Curr. Opin. Investig. Drugs 2, 1751-1756 (2001).
26. Carson DA, Seto S, Wasson DB, Carrera CJ. DNA strand breaks, NAD metabolism, and programmed cell death. Exp. Cell Res. 164, 273-281 (1986).
27. Seto S, Carrera CJ, Wasson DB, Carson DA. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J. Immunol. 136, 2839-2843 (1986).
28. Seto S, Carrera CJ, Wasson DB, Carson DA. Biochemical basis for deoxyadenosine and 2-chlorodeoxyadenosine toxicity to resting human lymphocytes. Adv. Exp. Med. Biol. 195(PtB), 577-582 (1986).
29. Beutler E, Koziol JA, McMillan R, Sipe JC, Romine JS, Carrera CJ. Marrow suppression produced by repeated doses of cladribine. Acta Haematol. 91, 10-15 (1994).
30. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc. Natl Acad. Sci. 93, 1716-1720 (1996).
31. Selby R, Brandwein J, O'Connor P. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis. Can. J. Neurol. Sci. 25, 295-299 (1998).
32. Friese MA, Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain 128, 1747-1763 (2005).
33. Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv. Exp. Med. Biol. 309A, 15-18 (1991).
34. Saven A, Kawasaki H, Carrera CJ. 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol. 11, 671-678 (1993).
35. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′- deoxyadenosine in humans. Cancer Res. 51, 5570-5572 (1991).
36. Liliemark J, Albertioni F, Hassan M, Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2′-deoxyadenosine in humans: alternative routes of administration. J. Clin. Oncol. 10, 1514-1518 (1992).
37. Grieb P, Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M. Effect of repeated treatments with cladribine (2-chlorodeoxyadenosine) on blood counts in multiple sclerosis patients. Arch. Immunol. Ther. Exp. 43, 323-327 (1995).
38. Romine JS, Sipe JC, Koziol JA, Zyroff J, Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc. Assoc. Am. Physicians 111, 35-44 (1999).
39. Beutler E, Sipe J, Romine J, McMillan R, Zyroff J, Koziol J. Treatment of multiple sclerosis and other autoimmune diseases with cladribine. Semin. Hematol. 33, 45-52 (1996).
40. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344, 9-13 (1994).
41. Serono Press Release. Serono and IVAX to initiate phase III clinical trial of Mylinax in multiple sclerosis. 1-11-2005.
42. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. J. Clin. Oncol. 13, 2431-2448 (1995).
43. Sipe JC, Knobler RL, Braheny SL, Rice GP, Panitch HS, Oldstone MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34, 1368-1372 (1984).
44. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54, 1145-1155 (2000).
45. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55, 1714-1718 (2000).
46. Filippi M, Rovaris M, Rice GP. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J. Neurol. Sci. 176, 42-44 (2000).
47. Adams HP, Wagner S, Sobel DF. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. Eur. Neurol. 42, 52-63 (1999).
48. Koziol JA, Frutos A, Sipe JC, Romine JS, Beutler E. A comparison of two neurologic scoring instruments for multiple sclerosis. J. Neurol. 243, 209-213 (1996).
49. Goodin DS. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology 18, 53-63 (1999).
50. Beutler E, Koziol JA. The cladribine trial in secondary progressive multiple sclerosis: a reanalysis. Neuroepidemiology 19, 109-112 (2000).
51. Goodin DS. The cladribine trial in secondary progressive MS: response. Neuroepidemiology 19, 53-54 (2000).
52. Bartosik-Psujek H, Stelmasiak Z, Mitosek-Szewczyk K, Belniak-Legiec E, Dobosz B. The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine). Ann. Univ. Mariae Curie Sklodowska (Med) 55, 231-234 (2000).
53. Bartosik-Psujek H, Belniak E, Mitosek-Szewczyk K, Dobosz B, Stelmasiak Z. Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand. 109, 390-392 (2004).
54. Niezgoda A, Losy J, Mehta PD. Effect of cladribine treatment on β-2 microglobulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol. 60, 225-228 (2001).